Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Duration of alectinib therapy

Time frame: From start of treatment to the date of treatment discontinuation (up to approximately 2.5 years)

Participant demographics by disease stage and city tier

Time frame: Up to approximately 2.5 years

Participant clinical characteristics as determined by Eastern Cooperative Oncology Group performance status (ECOG PS) by disease stage and city tier

Time frame: Up to approximately 2.5 years

Participant clinical characteristics as determined by surgery history by disease stage and city tier

Time frame: Up to approximately 2.5 years

Emotional and physical functioning as determined by the 36-item short form survey (SF-36) v2 questionnaires

Time frame: At enrollment, then every approximately 3 months thereafter (up to approximately 2.5 years)

Incidence and severity of adverse events (AEs)

Time frame: Baseline to withdrawal from study or 28 days after the last dose of alectinib, whichever occurs first